List of Excipients in Branded Drug ZELBORAF

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Genentech Inc	ZELBORAF	vemurafenib	50242-090	CROSCARMELLOSE SODIUM	2032-06-06
Genentech Inc	ZELBORAF	vemurafenib	50242-090	FERRIC OXIDE RED	2032-06-06
Genentech Inc	ZELBORAF	vemurafenib	50242-090	HYDROXYPROPYL CELLULOSE	2032-06-06
Genentech Inc	ZELBORAF	vemurafenib	50242-090	HYPROMELLOSE ACETATE SUCCINATE 16070722	2032-06-06
Genentech Inc	ZELBORAF	vemurafenib	50242-090	POLYETHYLENE GLYCOL 3350	2032-06-06
Genentech Inc	ZELBORAF	vemurafenib	50242-090	POLYVINYL ALCOHOL	2032-06-06

ZELBORAF Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: August 22, 2026

ZELBORAF, the brand name for vemurafenib, is a 240 mg immediate-release film-coated tablet marketed by Genentech, a Roche company. Its excipient profile is conventional but commercially relevant because vemurafenib has poor aqueous solubility, a high daily dose, and clinically important absorption behavior. The strongest opportunities are generic formulation development, excipient substitution, co-processed excipients, manufacturing efficiency, and differentiated oral dosage forms.

The primary commercial constraint is patent timing. U.S. composition-of-matter protection has been supplemented by formulation and method-of-use patents. Generic companies can pursue Paragraph IV strategies, but a successful product must address both patent claims and bioequivalence risks associated with vemurafenib dissolution and food effects.

What is ZELBORAF and how is it formulated?

ZELBORAF contains vemurafenib, a selective inhibitor of BRAF V600E and related BRAF mutations. The FDA approved the product in August 2011 for unresectable or metastatic melanoma with BRAF V600E mutation, later expanding use to Erdheim-Chester disease with BRAF V600 mutation [1].

The approved dosage is 960 mg per day, administered as four 240 mg tablets twice daily. The dose creates a meaningful tablet-burden problem. A generic developer that reduces tablet size, improves mechanical robustness, or develops a suitable alternative dosage form could gain a commercial advantage.

ZELBORAF dosage-form profile

Attribute	ZELBORAF profile
Active ingredient	Vemurafenib
Strength	240 mg per tablet
Daily dose	960 mg
Dosage form	Immediate-release film-coated tablet
Administration	Four tablets twice daily
Therapeutic class	BRAF kinase inhibitor
Originator	Genentech/Roche
FDA approval	August 17, 2011
Main indications	BRAF V600E metastatic melanoma; BRAF V600-mutant Erdheim-Chester disease
Regulatory pathway	New drug application
Biosimilar status	Not applicable; vemurafenib is a small molecule

What excipients are used in ZELBORAF tablets?

The U.S. product labeling identifies standard tablet-core and film-coating materials. Public labeling identifies excipients including microcrystalline cellulose, croscarmellose sodium, colloidal silicon dioxide, magnesium stearate, polyvinyl alcohol, polyethylene glycol, talc, titanium dioxide, and red iron oxide [1,2]. Regulatory formulations may describe certain materials using regional nomenclature, such as macrogol for polyethylene glycol and colloidal anhydrous silica for colloidal silicon dioxide.

Functional role of the ZELBORAF excipients

Excipient	Primary function	Commercial relevance
Microcrystalline cellulose	Diluent and compression aid	High-volume, readily substitutable component
Croscarmellose sodium	Superdisintegrant	Directly affects tablet breakup and dissolution
Colloidal silicon dioxide	Glidant and moisture-control aid	Supports powder flow and manufacturing consistency
Magnesium stearate	Lubricant	Over-lubrication can slow dissolution
Polyvinyl alcohol	Film-forming polymer	Supports coating uniformity and mechanical protection
Polyethylene glycol/macrogol	Plasticizer	Influences coating flexibility and drying
Talc	Anti-tacking and coating aid	May affect coating process economics
Titanium dioxide	Opacifier and color modifier	Subject to regional regulatory and customer restrictions
Red iron oxide	Colorant	Supports product identification and brand matching

The most technically sensitive excipients are croscarmellose sodium, magnesium stearate, the diluent system, and the coating package. Changes in particle size, grade, moisture content, surface area, or supplier can alter disintegration, dissolution, hardness, friability, and stability.

Why does vemurafenib create an excipient opportunity?

Vemurafenib is a low-solubility active pharmaceutical ingredient. The formulation must deliver consistent dissolution despite a large dose and limited tablet volume. FDA labeling also documents a food effect, with high-fat meals increasing exposure relative to fasting administration [1]. That pharmacokinetic behavior makes formulation equivalence more difficult than simple qualitative and quantitative matching.

The principal formulation challenges are:

1. Achieving rapid and reproducible dissolution.
2. Controlling the impact of lubricant concentration and blending time.
3. Maintaining tablet strength at high drug loading.
4. Managing polymorphism, particle-size distribution, and wetting.
5. Preserving bioequivalence under fed and fasting conditions.
6. Limiting tablet weight while maintaining manufacturability.
7. Controlling coating color and appearance for market recognition.

A supplier that can improve wetting or disintegration without introducing a new excipient-specific regulatory burden may have a stronger commercial proposition than a low-cost commodity supplier.

What excipient substitutions could support a generic ZELBORAF?

A generic formulation does not necessarily need to copy every inactive ingredient in the reference listed drug. The developer must demonstrate pharmaceutical equivalence and bioequivalence, while assessing safety, quality, and performance of each excipient.

Direct-substitution strategy

The lowest-risk strategy uses established grades of the same functional excipients:

• Microcrystalline cellulose from an alternate qualified supplier.
• Croscarmellose sodium with a comparable substitution profile.
• Magnesium stearate with controlled particle size and fatty-acid composition.
• Colloidal silicon dioxide with equivalent surface-area characteristics.
• Polyvinyl alcohol and polyethylene glycol in the film coat.

This route minimizes toxicology and regulatory risk. The opportunity for excipient companies is supply-chain qualification, dual sourcing, technical transfer, and validated equivalence rather than a novel formulation claim.

Co-processed excipient strategy

Co-processed excipients could improve powder flow, compactability, or disintegration. Potential platforms include combinations of:

• Microcrystalline cellulose and silicified microcrystalline cellulose.
• Cellulose-based diluents with superdisintegrants.
• Coprocessed filler-binder systems.
• Direct-compression platforms with improved flow and low lubricant sensitivity.

The commercial value is greatest if the platform enables a smaller tablet, reduces compression force, improves content uniformity, or shortens manufacturing cycle time. A generic sponsor must still establish that the platform does not create a dissolution profile materially different from the reference product.

Wetting and dissolution strategy

Because vemurafenib has low solubility, developers may evaluate:

• Surfactant-assisted wetting.
• Hydrophilic polymer systems.
• Amorphous or partially amorphous dispersion approaches.
• Particle-size reduction.
• Spray-dried intermediates.
• Lipid-based or self-emulsifying systems.
• Fast-disintegrating tablet structures.

These approaches may provide technical benefits but carry higher development and regulatory risks. They can also move the product away from a straightforward tablet-copy strategy and raise questions about drug-product sameness, stability, and food-effect comparability.

Film-coating strategy

The coating is a practical area for cost reduction and supply-chain differentiation. Opportunities include:

• Titanium-dioxide-free systems where permitted.
• Lower-cost color-matching systems.
• Faster-drying coating formulations.
• Reduced coating weight.
• Improved resistance to chipping and abrasion.
• Supplier-qualified premixes that reduce batch variability.

Color matching matters because ZELBORAF tablets have a distinctive appearance. A generic product does not need to reproduce the brand exactly, but it must comply with labeling, identification, and appearance requirements.

What patents protect ZELBORAF?

ZELBORAF is protected by a portfolio covering the vemurafenib chemical entity, pharmaceutical compositions, and therapeutic uses. Key U.S. patent numbers commonly associated with the product include US 7,863,288, US 8,501,709, and US 8,969,371. Patent scope and expiration depend on claim construction, patent-term adjustment, terminal disclaimers, pediatric extension, and jurisdictional status [3,4].

Patent	General subject matter	Commercial implication
US 7,863,288	Vemurafenib-related chemical compounds	Core composition-of-matter protection
US 8,501,709	Pharmaceutical composition or related compound coverage	May affect product design and generic entry
US 8,969,371	Formulation or pharmaceutical-use claims associated with vemurafenib	Potential barrier for specific formulations or uses

The core composition patent is generally reported to expire in the mid-to-late 2020s after patent-term adjustments. Later formulation or use patents may extend relevant protection into the late 2020s or early 2030s, depending on the specific claim and jurisdiction. The Orange Book remains the controlling source for listed U.S. patents and pediatric exclusivity status [3].

When does ZELBORAF lose exclusivity?

ZELBORAF’s five-year new chemical entity exclusivity expired in 2016. That exclusivity prevented submission of an abbreviated new drug application during the initial five-year period, subject to statutory exceptions.

The commercially relevant barriers after NCE exclusivity are patents, not regulatory exclusivity. A generic company can submit an ANDA with a Paragraph IV certification against listed patents before all patents expire. The applicant may seek a 180-day generic exclusivity period if it is the first qualified Paragraph IV filer and satisfies the applicable statutory conditions.

ZELBORAF exclusivity timeline

Date or period	Event
2011	FDA approval of ZELBORAF
2011-2016	Five-year NCE exclusivity period
2016 onward	ANDA filing possible, subject to patent certifications
Late 2020s	Core patent protection generally reaches expiry in the principal U.S. strategy
Late 2020s to early 2030s	Later formulation or method-of-use claims may affect specific products or indications

A generic launch before final patent expiry can occur through a court judgment, settlement license, invalidity decision, non-infringement position, or an authorized generic arrangement.

Are there Paragraph IV challenges to ZELBORAF?

Paragraph IV risk is structurally credible because ZELBORAF is a small-molecule oral tablet with expired NCE exclusivity. The most likely ANDA strategy would target the product’s active ingredient and tablet formulation while certifying that listed patents are invalid, unenforceable, or not infringed.

The principal technical arguments may involve:

• Non-infringement of composition claims through a distinct salt, crystal form, or formulation, if permitted by the patent scope.
• Non-infringement of formulation claims through excipient selection or manufacturing process.
• Invalidity based on obviousness, anticipation, written description, enablement, or patent-term issues.
• Carve-out of patented methods of use where permitted under the FDA’s labeling rules.
• A Paragraph III certification for patents that remain valid and enforceable until expiration.

A generic developer should expect patent litigation risk to center on composition claims and any later patents that cover a specific tablet composition, dose, or patient population.

What formulation patents may affect generic ZELBORAF?

Formulation patents are commercially important when they claim more than a routine tablet. Relevant claim features can include:

• Specific excipient ratios.
• A defined dissolution profile.
• Particle-size limits.
• Particular polymorphic or crystalline forms.
• Solid dispersions or enhanced-solubility systems.
• Tablet hardness or disintegration parameters.
• Specific dosing regimens tied to the formulation.

A generic that uses the reference product’s broad excipient architecture may reduce development risk but could fall within formulation claims if the claims are drafted around functional or quantitative limitations. A deliberately differentiated excipient system may improve freedom to operate, but it can increase bioequivalence and CMC risk.

What is the FDA and Orange Book status of ZELBORAF?

ZELBORAF is approved under an NDA and is listed in the FDA Orange Book as a prescription small-molecule product. It is not subject to the biosimilar pathway. Generic versions must proceed through an ANDA or, in some circumstances, a 505(b)(2) application.

The Orange Book analysis should distinguish:

• Patents listed for the reference product.
• Pediatric exclusivity attached to any listed patent.
• Product-specific patent expiration dates.
• Whether a patent covers the drug substance, drug product, or method of use.
• Whether a proposed generic label can omit patented indications.

FDA labeling identifies BRAF V600E melanoma and BRAF V600-mutant Erdheim-Chester disease uses. A generic applicant may face separate method-of-use considerations for the later indication, even if the drug-substance patent has expired.

Which companies compete with ZELBORAF?

ZELBORAF competes within the BRAF and MAPK pathway market. The main therapeutic comparators include TAFINLAR, BRAFTOVI, MEKTOVI, and combination regimens using a BRAF inhibitor with a MEK inhibitor.

Product	Active ingredient	Company	Competitive position
ZELBORAF	Vemurafenib	Genentech/Roche	BRAF V600-targeted therapy
TAFINLAR	Dabrafenib	Novartis	BRAF inhibitor, commonly combined with trametinib
BRAFTOVI	Encorafenib	Pfizer, previously Array/Bristol Myers Squibb rights structure	BRAF inhibitor with distinct pharmacology
MEKTOVI	Binimetinib	Pfizer	MEK inhibitor used with encorafenib
COTELLIC	Cobimetinib	Roche	MEK inhibitor used with vemurafenib

ZELBORAF’s commercial position is affected by combination therapy trends. In melanoma, BRAF/MEK combinations have reduced the role of BRAF monotherapy. That creates pressure on future branded revenue but may increase the value of low-cost generic vemurafenib in settings where monotherapy remains clinically appropriate or where access constraints influence treatment selection.

What licensing deals affect ZELBORAF?

Plexxikon discovered vemurafenib, and Roche acquired Plexxikon in 2011 for approximately $935 million upfront, with up to $130 million in contingent milestone payments reported at the time [5]. The transaction placed the ZELBORAF program within Roche’s oncology portfolio and consolidated control over development, commercialization, and related intellectual property.

This transaction matters for commercial diligence because:

• Roche controls the originator commercial strategy.
• Plexxikon-originated patent rights are integrated into the Roche/Genentech estate.
• Any authorized-generic or regional licensing opportunity would likely require Roche participation.
• The transaction does not create a separate biosimilar opportunity because vemurafenib is chemically synthesized.

How strong is the ZELBORAF patent estate?

The estate is strongest against an unmodified copy that relies on the same active ingredient and enters before core composition claims expire. It is weaker where a challenger can establish invalidity or design around later formulation and method-of-use claims.

Patent-strength assessment

Area	Relative strength	Reason
Core active ingredient	High before expiry	Composition claims can block all conventional tablet copies
Basic immediate-release tablet	Moderate	Routine excipient substitutions may avoid narrow formulation claims
Specific formulation ratios	Variable	Risk depends on claim breadth and prosecution history
Method of use	Moderate	Label carve-outs may reduce exposure
Manufacturing process	Variable	Process claims are difficult to detect but can affect supply-chain design
Biosimilar protection	Not applicable	Product is a small molecule

The main freedom-to-operate risk is not the use of any particular commodity excipient. It is the combination of active ingredient, solid-state form, formulation architecture, and labeled indication.

What generic launch scenarios exist for ZELBORAF?

Three launch scenarios are commercially plausible.

At-risk Paragraph IV launch

A first filer launches before patent expiry after receiving FDA approval and accepting litigation exposure. This can create significant damages risk if the originator prevails. The opportunity is highest where the challenger has a strong invalidity case and a differentiated formulation.

Licensed or settlement launch

The generic company receives a future entry date, potentially with an authorized-generic arrangement or supply agreement. The launch date depends on negotiated patent terms and any first-filer exclusivity.

Post-expiry launch

Multiple manufacturers enter after core patents expire. Price erosion can be rapid, particularly because the dosage form is a conventional tablet and the product has no biologic manufacturing barrier.

What commercial opportunities exist for excipient suppliers?

The largest excipient opportunities are linked to generic development and supply-chain optimization rather than originator reformulation.

Priority opportunities

1. High-functionality direct-compression excipients that improve tablet strength at high drug loading.
2. Superdisintegrants with reproducible performance across scale.
3. Low-lubricant-sensitivity formulations that preserve dissolution.
4. Coating premixes with rapid processing and robust color matching.
5. Excipient systems that reduce tablet weight or tablet count.
6. Dual-source materials with strong regulatory documentation.
7. Solubility-enhancing platforms supported by comparative dissolution data.
8. Regional reformulations that avoid restricted colorants or titanium dioxide.

Excipient companies with the strongest value proposition will provide formulation support, compendial compliance, extractables and leachables data where relevant, supplier continuity, and a package suitable for ANDA CMC documentation.

Key Takeaways

• ZELBORAF is a 240 mg immediate-release vemurafenib tablet requiring four tablets twice daily.
• The product uses conventional excipients, including microcrystalline cellulose, croscarmellose sodium, colloidal silicon dioxide, magnesium stearate, and a polyvinyl alcohol-based film coat.
• Vemurafenib’s low solubility, high dose, and food effect create meaningful formulation and bioequivalence challenges.
• NCE exclusivity expired in 2016; patent protection remains the principal U.S. entry barrier.
• Key publicly associated patents include US 7,863,288, US 8,501,709, and US 8,969,371.
• The best excipient opportunities are co-processed direct-compression systems, dissolution-control technologies, coating premixes, and qualified alternate sources.
• Vemurafenib has no biosimilar pathway. Competition will come from ANDA generics and branded BRAF/MEK alternatives.
• A successful generic strategy should combine patent design-around analysis with comparative dissolution, fed/fasted bioequivalence planning, and supply-chain qualification.

FAQs

Can a generic ZELBORAF use different excipients?

Yes. An ANDA applicant may use different inactive ingredients if the formulation meets FDA safety, quality, pharmaceutical-equivalence, and bioequivalence requirements. Differences in excipient grade or concentration must be evaluated for their effect on dissolution and stability.

Is there an opportunity for a liquid vemurafenib formulation?

Potentially, but a liquid formulation would create substantial development and regulatory work. Solubility, chemical stability, taste, dosing accuracy, container compatibility, and pediatric suitability would require a new formulation strategy rather than a simple generic copy.

Does ZELBORAF require a biosimilar application?

No. Vemurafenib is a chemically synthesized small molecule. A generic applicant would normally use the ANDA pathway, not the 351(k) biosimilar pathway.

Can a generic omit the Erdheim-Chester disease indication?

A generic applicant may seek a labeling carve-out for a patented method of use if FDA rules permit the omission and the remaining label supports approval. The commercial effect depends on whether the omitted indication represents a material share of demand.

Which excipient has the greatest impact on ZELBORAF dissolution?

Croscarmellose sodium, magnesium stearate, the diluent system, and the active ingredient’s particle characteristics are likely to have the greatest direct impact. Excessive magnesium stearate or prolonged lubrication can reduce wetting and slow tablet dissolution.

References

1. Genentech, Inc. (2023). ZELBORAF (vemurafenib) tablets, prescribing information. U.S. Food and Drug Administration.

2. National Library of Medicine. (2024). DailyMed: ZELBORAF- vemurafenib tablet, film coated. U.S. National Library of Medicine.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

4. U.S. Patent and Trademark Office. (2024). Patent Center and Patent Examination Data System records for U.S. Patents 7,863,288, 8,501,709, and 8,969,371. USPTO.

5. Roche. (2011, May 16). Roche to acquire Plexxikon, a privately held biotechnology company. Roche press release.